Stephen T. Sonis

Stephen T. Sonis is Professor of Oral Medicine at Harvard, Brigham and Women’s Hospital and the Dana-Farber Cancer Institute and a world-renowned expert in epithelial injury associated with cancer therapy. His development of predictive models has enabled the investigation of the biological basis of cancer regimen-related adverse effects and has stimulated the development of potential therapies. Dr. Sonis served as President of Triad, which focused on the adverse health and economic outcomes of cancer treatment toxicities and founded Biomodels and Primary Endpoint Solutions to catalyze the development of drugs, devices, and biologicals for a variety of indications. He is a special government employee of the FDA, holds several patents, and has authored more than 300 original publications.